HSF1 and amyotrophic lateral sclerosis: The therapeutic potential of HSF1 is further bolstered by the finding that Riluzole, an FDA-approved drug that has a moderate but reproducible effect on extending ALS patient survival72, is thought to at least in part, elicit its benefit by increasing latent HSF1 levels73.